At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
GS-9674 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)
In Brief
A Phase 2 clinical trial evaluating GS-9674 and Placebo to match GS-9674 for Nonalcoholic Steatohepatitis (NASH). Completed, enrolled 140 participants across 37 sites in 6 countries.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis (NASH)
CountriesCanada, Hong Kong, New Zealand, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartOct 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedAug 3, 2016
Enrollment StartOct 26, 2016
Primary CompletionJan 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.9 years ago
Interventions
GS-9674drug
Tablet administered orally once daily
Placebo to match GS-9674drug
Tablet(s) administered orally once daily